Aimmune is poised to deliver the first-ever US Food and Drug Administration (FDA)-approved therapy for peanut allergy in a once-daily oral medicine.* If approved, AR101 will be a first-in-class therapy offering precise, reliable dosing and consistent, reproducible potency for critical allergens.

Aimmune’s approach to treating food allergies builds on the oral immunotherapy concept, where the body’s immune system can be desensitized to certain food allergens by ingesting tiny doses of the specially processed allergen in gradually increasing amounts over time.